Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis

Shi, Jianwei; Lu, Da-Feng; Gu, Ruxin; Sun, Hongzhi; Yu, Li; Pan, Ruihan; Zhang, Yansong

doi:10.1016/j.amjoto.2021.103148

Cited by 14 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation may be useful, yet it bears the risk of malignant transformation. Auditory brainstem implants are a valuable option in cases where the cochlear nerve must be sacrificed [ 50 ]. Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor and has been shown as effective in reducing tumor size and improving hearing in nearly one-third of treated patients [ 51 ].…”

Section: Types Of Tumorsmentioning

confidence: 99%

Neurofibromatosis in Children: Actually and Perspectives

Sur

Armat²,

Sur

et al. 2022

Children

View full text Add to dashboard Cite

The three types of neurofibromatosis, namely type 1, type 2, and schwannomatosis, are generally associated with various benign tumors affecting the skin and the nervous system. On rare occasions, especially in patients with neurofibromatosis type 1 (NF1), malignant neoplasms may also be present, several of them possessing a more aggressive course than in individuals without this syndrome. As such, a clear delineation between the three variants of neurofibromatosis is crucial to establish the correct diagnosis and management, as well as predict the neoplasm-related outcomes. Neurofibromin, the principal product of the NF1 gene, is a potent inhibitor of cellular proliferation, having been linked to several key signaling pathways involved in tumor growth. Therefore, it may provide a useful therapeutic target for tumor management in these patients. In this article, we want to present the association between deficiency of neurofibromin and the consequences of the lack of this protein leading to different kinds of malignant tumors. The therapy is still uncertain and most therapeutic options are in development or clinical trials.

show abstract

Section: Types Of Tumorsmentioning

confidence: 99%

Neurofibromatosis in Children: Actually and Perspectives

Sur

Armat²,

Sur

et al. 2022

Children

View full text Add to dashboard Cite

show abstract

“…A meta-analysis reported a mean treatment period of 16 months. 253 In a retrospective study of 33 patients with NF2, 58% developed hypertension and 62% developed proteinuria, requiring dose adjustments. 254 Therefore, a low-dose regimen may be more appropriate in prolonged treatments.…”

Section: Resultsmentioning

confidence: 99%

Brazilian Society of Otology task force – Vestibular Schwannoma ‒ evaluation and treatment

Silva,

Lavinsky,

Pauna

et al. 2023

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

“…Bevacizumab may be considered as first-line medical therapy for rapidly growing VS. In a recent meta-analysis, the median treatment duration was 16 months [ 18 , 19 ]. Recently, the first phase III randomized clinical trial using bevacizumab was conducted in Japan [ 20 , 21 ].…”

Section: Protein-kinase-related Pathwaymentioning

confidence: 99%

A Critical Overview of Targeted Therapies for Vestibular Schwannoma

Tamura

Toda

2022

IJMS

View full text Add to dashboard Cite

Vestibular schwannoma (VS) is a benign tumor that originates from Schwann cells in the vestibular component. Surgical treatment for VS has gradually declined over the past few decades, especially for small tumors. Gamma knife radiosurgery has become an accepted treatment for VS, with a high rate of tumor control. For neurofibromatosis type 2 (NF2)-associated VS resistant to radiotherapy, vascular endothelial growth factor (VEGF)-A/VEGF receptor (VEGFR)-targeted therapy (e.g., bevacizumab) may become the first-line therapy. Recently, a clinical trial using a VEGFR1/2 peptide vaccine was also conducted in patients with progressive NF2-associated schwannomas, which was the first immunotherapeutic approach for NF2 patients. Targeted therapies for the gene product of SH3PXD2A-HTRA1 fusion may be effective for sporadic VS. Several protein kinase inhibitors could be supportive to prevent tumor progression because merlin inhibits signaling by tyrosine receptor kinases and the activation of downstream pathways, including the Ras/Raf/MEK/ERK and PI3K/Akt/mTORC1 pathways. Tumor-microenvironment-targeted therapy may be supportive for the mainstays of management. The tumor-associated macrophage is the major component of immunosuppressive cells in schwannomas. Here, we present a critical overview of targeted therapies for VS. Multimodal therapy is required to manage patients with refractory VS.

show abstract

Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis

Cited by 14 publications

References 26 publications

Neurofibromatosis in Children: Actually and Perspectives

Neurofibromatosis in Children: Actually and Perspectives

Brazilian Society of Otology task force – Vestibular Schwannoma ‒ evaluation and treatment

A Critical Overview of Targeted Therapies for Vestibular Schwannoma

Contact Info

Product

Resources

About